Company Spotlight

Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
On his second day in office, President Trump annulled “Executive Order on Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence,” a 2023 Biden administration directive that highlighted the stance of the federal government on responsible artificial intelligence.
On January 20th, 2024, Donald Trump was sworn in as the 47th President of the United States of America, marking a swarm of changes in the country. President Trump passed a slew of orders on the very first day of his second term, set to bring in some noticeable changes to the global healthcare scenario in the coming years. As the world’s largest economy, the United States plays a critical role in shaping the trends in both the healthcare and pharmaceutical industry. Therefore, the changes are expected to bring a substantial impact across several industries. Let us examine in detail!
President Trump has signed an executive order to withdraw from the World Health Organization. The United States of America is the largest donor to the institution, contributing around 18% of the total income via voluntary funding. The exit follows the alleged mismanagement during the COVID-19 pandemic, along with the organization’s inability to offer effective methods that could have helped in reforming the global health crisis.
As the next step, the Assistant to the President for National Security Affairs plans to set up directorates in the National Security Council that will strengthen biosecurity and safeguard public health within the nation. The Organization will witness a cease on all government funds, support, or resources from the United States. All the Government personnel committed to the Organization shall be redirected. In the meantime, there will be more emphasis on solidifying the presence of the country's indigenous health forums like the US Centers for Disease Control and Prevention (CDC). While in the process of withdrawal, the State Secretary will stop WHO Pandemic Agreement negotiations, as well as the amendments around the International Health Regulations.
To manage the federal expenditure and minimize subsidiaries, the Trump government reversed Biden's Affordable Care Act (ACA) health plan. This health plan allowed people extra time to sign up for health insurance. Moreover, it provided additional subsidiaries so as to reduce premium costs and increased the funding for third-party organizations, enabling community groups and nonprofits to assist individuals with health insurance enrollment. With this, the Biden administration doubled their enrollment in ACA, reaching 24 million. However, most of these gains were achievable with the help of subsidies. By scaling back these efforts, the Trump administration indicates a way for broader policy differences that may strike a balance between assisting the masses with insurance while maintaining financial reserves.
Another major executive order is focused on CMMI, the Center for Medicare and Medicaid Innovation. It was established under the Affordable Care Act to test and implement innovative payment and service delivery models. The vision was to improve healthcare quality while reducing costs by following three experimental drug pricing models. The pricing models entail a multi-state Medicaid agreement for high-cost therapies like cell and gene therapies. These therapies are life altering but may come off as extremely expensive. Hence, the state would intervene via pooling resources and negotiating with drug manufacturers. The second pricing model is intended to lower payments for drugs with accelerated FDA approvals. Lastly, the third model intends to encourage Medicare prescription drug plans to offer affordable and consistent access to generic medications, particularly for common chronic conditions, such as diabetes, hypertension, or high cholesterol. With current orders implemented by the Trump government, it is unclear if the new CMMI administration will proceed with or modify these experiments.
The Trump administration has directed a hold on regulatory authorities until the new Department of Health and Human Services (HHS) leadership evaluates which Biden-era regulations will stay or let go of. This tradition has been persistent during the first Trump administration (2017) as well as the Biden administration tenure (2021). The hold is intended to allow the officials to gain a better understanding of where things stand at the moment. They will offer proposed updates on the HIPAA Security Rule and the proposed rule for prescribing controlled substances via telehealth. These rules were finalized during the Biden tenure but are yet to be effective and have been postponed for 60 days.
As per a press release issued by the White House on February 1st, 2025, the Trump administration levied 25% tariffs on Canadian and Mexican imports along with 10% tariff on imports from China. The tariffs are imposed to pause the flow of chemicals as well as illegimate drugs like fentanyl into the country. This decision could lead to a significant effect on the domestic pharmaceutical and life sciences industry potentially fostering a competitive manufacturing landscape. Addressing to the move, John Murphy III, CEO of the Association for Accessible Medicines (AAM) indicated a possible disruption in biopharmaceutical supply chain, leading to drug shortages. Meanwhile, the president and CEO of the National Association of Manufacturers, Jay Timmons, took a more balanced stance, acknowledging that the manufacturers need to recognize and address issues related to illicit drug trafficking.
On his second day in office, President Trump annulled “Executive Order on Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence,” a 2023 Biden administration directive that highlighted the stance of the federal government on responsible artificial intelligence. The new order signed on January 23, 2025, outlined Trump's overview of a more liberal integration of artificial intelligence. The fact sheet issued by his administration mentioned that "American development of AI systems must be free from ideological bias or engineered social agendas,". In addition, the new order issues another action plan boosting infrastructure for better AI integration and involves a joint venture between OpenAI, Oracle and SoftBank that may scale up to USD 500 billion.
As we progress into an era of robotics and artificial intelligence, such investments can prove to be pivotal in bringing more advanced solutions into the medical ecosystem. As per EMR analysis, the North America artificial intelligence in healthcare market is anticipated to grow at a CAGR of 48.10% during the forecast period of 2025-2034. The current shift in power dynamics is bringing both applause and scrutiny to the newly re-elected president. Ultimately, current changes will transform the role of the United States in global healthcare leadership. It is clear that the government is moving in a direction to bolster its domestic agenda and get a better grip on technology. The outcomes will gradually unfold with time, reshaping the landscape of healthcare systems across the world.
Latest Updates on Thriving Economically in a World of Constant Innovation
To place an order through our website, select the license type mentioned on the report details page. Click on the ‘Buy Now’ button and fill in your details. Select your preferred mode of payment after which you will be redirected to the selected payment gateway. Follow the steps and proceed to checkout.
www.expertmarketresearch.comEnlisting all your requirements and queries along with details that include billing and delivery address and the preferred payment mode. Our customer service representative will revert to you within 24 hours.
[email protected]To place an order through telephone, call our sales team on the following numbers and our customer service representative will help you regarding the same.
+61 291 889 415Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124